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Transrectal ultrasound-guided prostate (TRUS-P) needle biopsy is a common procedure for detection of
prostate cancer. Complications associated with TRUS-P biopsy are almost always minor and do not
require hospitalization. Pelvic hematoma following TRUS-P biopsy is an extremely rare complication.
Only a few cases have been reported in the past. Here we report the case of a 67-year-old man diagnosed
with pelvic hematoma following TRUS-P biopsy who presented with tenderness in the lower abdomen
and ecchymosis in the paraumbilical region, lower abdomen, and scrotum. To our knowledge, no other
case has been reported in Taiwan. Therefore, we discuss this case report and review the literature
associated with complication of TRUS-P biopsies.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Prostate cancer is common in geriatric populations. Since 1995,
approximately 2,600,000 men in the United States have been
diagnosed with prostate cancer, and nearly 375,000 of them have
lost their lives to this disease.1 Prostate cancer is also the seventh
leading cause of cancer mortality in Taiwan. The overall incidence
of prostate cancer in Taiwan increased by almost 50% from 1998 to
2007.2 Also, the widespread use of prostate-speciﬁc antigen (PSA)
measurement for screening in general population has led to a
dramatic increase in the number of prostate biopsies performed in
Taiwan. Consequently, complications associated with transrectal
ultrasound-guided prostate (TRUS-P) needle biopsy need to be
monitored carefully.2. Case report
A 67-year-old Taiwanese man was diagnosed with benign
prostate hyperplasia. Follow-up was conducted on an outpatient
basis. A tumor marker screening test showed elevated PSA levels
(7.114 ng/mL), the free-form PSA levels (0.624 ng/mL), and a
decreased free-to-total PSA ratio (8.8%). Digital rectal examination
revealed that the consistency of the prostate was ﬁrm and a hardNational Taiwan University
rsity, Number 7, Chung Shan
Taiwan.
ng).
blished by Elsevier Taiwan LLC. Opnodule was palpable in the left lateral prostate lobe. The prostate
gland visualized using the transrectal ultrasound (TRUS) was
4.5 cm  3.5 cm  5.6 cm (width  height  length) with an
estimated mass of 46.2 g. The patient had no medical history of
antiplatelet or anticoagulant drug therapy. Under intravenous
general anesthesia, standard 12-core biopsy was performed using
TRUS-guided. Three cores each of prostate tissue were obtained
from the left lateral, left paramedial, right paramedial, and right
lateral prostate lobes. In addition, three cores were obtained from
the hard nodule on the left lateral prostate lobe using digitally
directed transrectal needle biopsy. Pathological analysis of the bi-
opsies revealed benign prostate tissue.
The patient presented with lower abdominal tenderness and
ecchymosis in the paraumbilical region, the lower abdomen, and the
scrotum to the outpatient department 2 weeks after TRUS-P biopsy
(Fig. 1). Physical examination revealed no peritoneal signs. Digital
rectal examination revealed the same as prebiopsy ﬁndings.
Computed tomography (CT) revealed a 5.34 cm 9.75 cm 9.95 cm
(length width  height) pelvic hematoma (Figs. 2 and 3) with an
estimated volume of 269.38 mL. Laboratory examination showed a
decrease in hemoglobin concentration from 17.2 g/dL to 12.9 g/dL
since TRUS-P biopsy. Coagulopathy or bleeding tendency was not
evident. Prophylactic antibiotics were not prescribed as the patient
showed no signs of fever or infection during hospitalization. The
patient’s clinical condition was stable, so he was discharged and
followed up on an outpatient basis. At 1-year follow-up, there were
no symptoms of the hematoma recurrence, or presence of infection.
The patient ﬁt the normal life.en access under CC BY-NC-ND license.
Fig. 1. Ecchymosis in the paraumbilical area and the lower abdomen (arrows).
Fig. 3. Pelvic hematoma anterior to the urinary bladder (length).
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Prostate cancer is common in geriatric populations. Although
serum PSA testing is the most reliable method of early detection,
TRUS-P biopsy is still the gold standard technique to conﬁrm the
diagnosis of prostate cancer. TRUS-P biopsy enables sampling from
palpable or nonpalpable lesions, including hypoechoic masses
visualized using ultrasound. Some clinicians may perform staging
biopsies to identify extraprostatic invasion, which helps in the se-
lection of treatment options.3 TRUS-P biopsy may be associated
with several complications, most of which are minor and do not
require hospitalization.
Table 14e9 lists the recent studies reporting complications
related to bleeding after TRUS-P biopsy.4e9 In these studies, the
incidence of hematuria varied due to differences in the deﬁnition of
hematuria and timing of interview. Berger et al4 recorded the
incidence of complications via personal or telephonic interviews 2
weeks after biopsy, and this incidence was much lower than that
recorded in the study by Raaijmakers et al,5 wherein data on
complications were collected 2e3 weeks after biopsy via ques-
tionnaires. Rietbergen et al6 also used a questionnaire to collect
data regarding complications similar to that used by Raaijmakers
et al5; therefore, the incidence of hematuria and hematospermia
was similar in both studies. Djavan et al7 collected data regarding
complications on the basis of a personal interview 7 days after bi-
opsy. This shorter interval may account for the lower incidence of
hematospermia (9.8%) in their study. A shorter follow-up periodFig. 2. Pelvic hematoma anterior to the urinary bladder (width  height).may lower the incidence of hematospermia because many patients
may not have had a chance to ejaculate. In another recent study,
Kakehi and Naito8 reported a large review of medical records of
212,065 biopsies performed in Japan. Unfortunately, hematuria,
hematospermia, and rectal bleeding were not deﬁned in that study.
Finally, Ghani et al9 reported a high incidence of bleeding compli-
cations in the ﬁrst 7 days after TRUS-P biopsy, as assessed by
questionnaire. Early assessment may be the reason for a higher
incidence in their study compared with that in other studies.
Although bleeding complications are common, pelvic hema-
toma following TRUS-P biopsy is extremely rare. Wendel and
Evans10 were the ﬁrst to report this complication following TRUS-P
biopsy in 1967. Limited case reports of patients with this compli-
cation have been published after the initial report. Most hema-
tomas develop in the perivesical space, caused by injury to the
periprostatic venous plexus, inferior vesical artery, and middle
rectal artery.11 These vascular structures can be injured during
needle biopsy. The most common presentations include lower
abdominal tenderness, ecchymosis, constipation, and difﬁculty in
voiding, possibly because of compression from the hematoma on
adjacent organs. In other cases, antiplatelet or anticoagulant drugs
have been associated with pelvic hematoma following TRUS-P bi-
opsy. Seymour and Oesterling11 reported the case of a 79-year-old
man with a history of hypertension and atherosclerosis on regular
aspirin (325 mg qd) therapy. The patient withheld this information
from the medical personnel prior to the TRUS-P biopsy.11 The pa-
tient presented with an inability to void and defecate after the bi-
opsy. CT scan showed a hematoma measuring 8 cm  7 cm  9 cm
in the anterior rectal wall. Conservative treatment was followed. Six
months later, the hematoma had shrunk and the symptoms had
resolved. Hematomas have a risk of getting infected. InfectiousTable 1
Published studies reporting bleeding complication rates after TRUS-P biopsy.
Authors Patient/
biopsy
number
Biopsy
cores
Hematuria
(%)
Hematospermia
(%)
Rectal
bleeding
(%)
Berger et al4 4303 NA 14.5 36.3 2.3
Raaijmakers et al5 5802 6 22.6 50.4 1.3
Rietbergen et al6 1867 6e7 23.6 45.3 1.7
Djavan et al7 1015 8 62 9.8 2.1
Kakehi and
Naito 8
212,065 6 12 1.2 5.9
Ghani et al9 760 6e12 41.5 14.2 22.6
NA ¼ not available.
Table 2
Case reports associated with pelvic hematoma following TRUS-P biopsy.
Age
(y)
Symptoms Site Size Anticoagulant/
antiplatelet
Time to
symptoms
(after biopsy, d)
Treatment Ref.
66 Abdominal pain/suprapubic mass Perivesical space NA None 0.2 Conservative treatment 10
61 Suprapubic pain/suprapubic mass/ecchymosis Prevesical space NA None NA Conservative treatment 10
79 Suprapubic discomfort/perineal pain Anterior rectal wall
hematoma
262 mL Aspirin 325 mg
P.O Q.D
0.5 Conservative treatment 11
52 Lower abdominal pain/palpable mass Prevesical hematoma NA None <1 Conservative treatment 12
57 Fever/palpable mass Prevesical hematoma NA None 18 Open removal of hematoma 12
86 Suprapubic tenderness/shock Periprostate/perivesical >2500 mL None Immediately Open removal of hematoma 13
70 Constipation Pelvic hematoma 468 mL None 10 8 French Pigtail inserted to
hematoma
14
63 Perineal pain/perineal ecchymosis Postvesical hematoma NA None 90 Conservative treatment 14
67 Lower abdominal pain/periumbilical
ecchymosis
Prevesical/perivesical
hematoma
269 mL None 14 Conservative treatment Our
case
NA ¼ not available.
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Choyke et al12 reported the case of a 57-year-old manwith infected
prevesical hematoma following TRUS-P biopsy.
Treatment of pelvic hematoma following TRUS-P biopsy is still
controversial. Conservative treatment is followed in most cases.
Nevertheless, Mobly et al13 suggested that hematoma >2500 mL in
volume should be surgically removed. Some urologists recommend
drainage as well. Sacak et al14 reported the case of a 70-year-old
male presenting with constipation 10 days after TRUS-P biopsy.
Digital rectal examination, revealed a well-deﬁned mass in the
rectum. Suprapubic ultrasound revealed a 10 cm  10 cm  9 cm
cystic lesion in the pelvis. Pelvic hematoma was diagnosed on the
basis of these examinations. Transrectal ultrasound-guided inser-
tion of an 8F pigtail catheter was performed for drainage of the
hematoma. The hematoma had totally disappeared by Day 10 of
therapy. Case reports associated with pelvic hematoma following
TRUS-P biopsy are listed in Table 2.
In the case reported here, a 67-year-old Taiwanese man with no
history antiplatelet or anticoagulant drugs therapy underwent TRUS-
P biopsy. He presented to the outpatient department with lower
abdominal tenderness and ecchymosis in the paraumbilical region,
lower abdomen, and scrotum. CT scan revealed a hematoma of an
estimated volume of 269.38 mL in the prevesical and perivesical
space. This pelvic hematoma may have been induced by digitally
directed transrectal needle biopsy of the left lateral hard nodule
when the needle punctured the prostate capsule to injure the peri-
prostatic venous plexus. To our knowledge, this is the ﬁrst case of
hematoma associatedwith TRUS-P biopsy encountered and reported
in Taiwan. We share this rare complication to emphasize the
importance of the awareness of risks associated with TRUS-P biopsy.
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